Vyome Holdings, Inc
No SEC Form 4 filings for $HIND in the last 30 days.
See all $HIND insider activity →Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o
Over the past 7 days, alphai's AI scored 1 news story mentioning HIND (Vyome Holdings, Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Positive Phase 2 outcomes and FDA feedback may boost near‑term valuation; cash runway remains limited.
alphai scores every news story that mentions HIND with an AI model for sentiment and relevance, and aggregates insider trades from Vyome Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o
2 min read